Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.0% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 704,627 shares of the biopharmaceutical company's stock after purchasing an additional 46,347 shares during the period. Asset Management One Co. Ltd. owned approximately 0.06% of Gilead Sciences worth $78,953,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Redwood Financial Network Corp raised its position in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after purchasing an additional 98 shares during the last quarter. Nicolet Advisory Services LLC increased its position in Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after buying an additional 100 shares in the last quarter. Peak Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after acquiring an additional 100 shares during the last quarter. Perkins Coie Trust Co lifted its position in shares of Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after acquiring an additional 100 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. boosted its stake in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Trading Down 1.2%

GILD stock traded down $1.27 during midday trading on Wednesday, reaching $105.93. 6,053,341 shares of the company's stock traded hands, compared to its average volume of 7,638,237. Gilead Sciences, Inc. has a fifty-two week low of $66.01 and a fifty-two week high of $119.96. The business has a 50-day moving average price of $106.21 and a two-hundred day moving average price of $103.03. The company has a market capitalization of $131.77 billion, a P/E ratio of 22.30, a PEG ratio of 0.69 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the prior year, the company earned ($1.32) EPS. The firm's revenue was down .3% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares of the company's stock, valued at $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,500 shares of company stock worth $5,236,245. 0.27% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on GILD shares. Oppenheimer cut their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Bank of America boosted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.